11 results on '"Bax, Caroline J."'
Search Results
2. Effectiveness of a cervical pessary for women who did not deliver 48 h after threatened preterm labor (Assessment of perinatal outcome after specific treatment in early labor: Apostel VI trial)
- Author
-
Hermans, Frederik J R, Schuit, Ewoud, Opmeer, Brent C., Oudijk, Martijn A., Bekker, Mireille, Woiski, Mallory, Bax, Caroline J., Sueters, Marieke, Scheepers, Hubertina C J, Franssen, Maureen T M, Pajkrt, Eva, Mol, Ben Willem J, Kok, Marjolein, Hermans, Frederik J R, Schuit, Ewoud, Opmeer, Brent C., Oudijk, Martijn A., Bekker, Mireille, Woiski, Mallory, Bax, Caroline J., Sueters, Marieke, Scheepers, Hubertina C J, Franssen, Maureen T M, Pajkrt, Eva, Mol, Ben Willem J, and Kok, Marjolein
- Published
- 2016
3. Early nasogastric tube feeding in optimising treatment for hyperemesis gravidarum: the MOTHER randomised controlled trial (Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding)
- Author
-
Geboortecentrum voorzitterschap, Other research (not in main researchprogram), MS Verloskunde, Grooten, Iris J, Mol, Ben W, van der Post, Joris A M, Ris-Stalpers, Carrie, Kok, Marjolein, Bais, Joke M J, Bax, Caroline J, Duvekot, Johannes J, Bremer, Henk A, Porath, Martina M, Heidema, Wieteke M, Bloemenkamp, Kitty W M, Scheepers, Hubertina C J, Franssen, Maureen T M, Oudijk, Martijn A, Roseboom, Tessa J, Painter, Rebecca C, Geboortecentrum voorzitterschap, Other research (not in main researchprogram), MS Verloskunde, Grooten, Iris J, Mol, Ben W, van der Post, Joris A M, Ris-Stalpers, Carrie, Kok, Marjolein, Bais, Joke M J, Bax, Caroline J, Duvekot, Johannes J, Bremer, Henk A, Porath, Martina M, Heidema, Wieteke M, Bloemenkamp, Kitty W M, Scheepers, Hubertina C J, Franssen, Maureen T M, Oudijk, Martijn A, Roseboom, Tessa J, and Painter, Rebecca C
- Published
- 2016
4. Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour : APOSTEL III-Trial)
- Author
-
van Vliet, Elvira Og, Schuit, Ewoud, Heida, Karst Y, Opmeer, Brent C, Kok, Marjolein, Gyselaers, Wilfried, Porath, Martina M, Woiski, Mallory, Bax, Caroline J, Bloemenkamp, Kitty Wm, Scheepers, Hubertina Cj, Jaquemyn, Yves, van Beek, Erik, Duvekot, Hans Jj, Franssen, Maureen Tm, Bijvank, Bas N, Kok, Joke H, Franx, Arie, Mol, Ben Willem J, Oudijk, Martijn A, van Vliet, Elvira Og, Schuit, Ewoud, Heida, Karst Y, Opmeer, Brent C, Kok, Marjolein, Gyselaers, Wilfried, Porath, Martina M, Woiski, Mallory, Bax, Caroline J, Bloemenkamp, Kitty Wm, Scheepers, Hubertina Cj, Jaquemyn, Yves, van Beek, Erik, Duvekot, Hans Jj, Franssen, Maureen Tm, Bijvank, Bas N, Kok, Joke H, Franx, Arie, Mol, Ben Willem J, and Oudijk, Martijn A
- Published
- 2014
5. Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial)
- Author
-
MS Verloskunde, Epi Methoden Team 1, Arts-assistenten DV&B, Geboortecentrum voorzitterschap, Child Health, Brain, Other research (not in main researchprogram), van Vliet, Elvira Og, Schuit, Ewoud, Heida, Karst Y, Opmeer, Brent C, Kok, Marjolein, Gyselaers, Wilfried, Porath, Martina M, Woiski, Mallory, Bax, Caroline J, Bloemenkamp, Kitty Wm, Scheepers, Hubertina Cj, Jaquemyn, Yves, van Beek, Erik, Duvekot, Hans Jj, Franssen, Maureen Tm, Bijvank, Bas N, Kok, Joke H, Franx, Arie, Mol, Ben Willem J, Oudijk, Martijn A, MS Verloskunde, Epi Methoden Team 1, Arts-assistenten DV&B, Geboortecentrum voorzitterschap, Child Health, Brain, Other research (not in main researchprogram), van Vliet, Elvira Og, Schuit, Ewoud, Heida, Karst Y, Opmeer, Brent C, Kok, Marjolein, Gyselaers, Wilfried, Porath, Martina M, Woiski, Mallory, Bax, Caroline J, Bloemenkamp, Kitty Wm, Scheepers, Hubertina Cj, Jaquemyn, Yves, van Beek, Erik, Duvekot, Hans Jj, Franssen, Maureen Tm, Bijvank, Bas N, Kok, Joke H, Franx, Arie, Mol, Ben Willem J, and Oudijk, Martijn A
- Published
- 2014
6. Effectiveness of a cervical pessary for women who did not deliver 48 h after threatened preterm labor (Assessment of perinatal outcome after specific treatment in early labor: Apostel VI trial).
- Author
-
Hermans, Frederik J. R., Schuit, Ewoud, Opmeer, Brent C., Oudijk, Martijn A., Bekker, Mireille, Woiski, Mallory, Bax, Caroline J., Sueters, Marieke, Scheepers, Hubertina C. J., Franssen, Maureen T. M., Pajkrt, Eva, Mol, Ben Willem J., and Kok, Marjolein
- Subjects
PREMATURE labor ,CERVIX uteri ,DELIVERY (Obstetrics) ,LABOR complications (Obstetrics) ,DURATION of pregnancy ,PREMATURE infants ,ANTHROPOMETRY ,COMPARATIVE studies ,EXPERIMENTAL design ,FETAL ultrasonic imaging ,FIBRONECTINS ,RESEARCH methodology ,MEDICAL cooperation ,PESSARIES ,RESEARCH ,TIME ,EVALUATION research ,RANDOMIZED controlled trials ,ANATOMY ,PREVENTION - Abstract
Background: Preterm birth is a major cause of neonatal mortality and morbidity. As preventive strategies are largely ineffective, threatened preterm labor is a frequent problem that affects approximately 10 % of pregnancies. In recent years, risk assessment in these women has incorporated cervical length measurement and fetal fibronectin testing, and this has improved the capacity to identify women at increased risk for delivery within 14 days. Despite these improvements, risk for preterm birth continues to be increased in women who did not deliver after an episode of threatened preterm labor, as indicated by a preterm birth rate between 30 to 60 % in this group of women. Currently no effective treatment is available. Studies on maintenance tocolysis and progesterone have shown ambiguous results. The pessary has not been evaluated in women with threatened preterm labor, however studies in asymptomatic women with a short cervix show reduced rates of preterm birth rates as well as perinatal complications. The APOSTEL VI trial aims to assess the effectiveness of a cervical pessary in women who did not deliver within 48 h after an episode of threatened preterm labor.Methods/design: This is a nationwide multicenter open-label randomized clinical trial. Women with a singleton or twin gestation with intact membranes, who were admitted for threatened preterm labor, at a gestational age between 24 and 34 weeks, a cervical length between 15 and 30 mm and a positive fibronectin test or a cervical length below 15 mm, who did not deliver after 48 h will be eligible for inclusion. Women will be allocated to a pessary or no intervention (usual care). Primary outcome is preterm delivery < 37 weeks. Secondary outcomes are amongst others a composite of perinatal morbidity and mortality. Sample size is based on an expected 50 % reduction of preterm birth before 37 weeks (two-sided test, α 0.05 and β 0.2). Two hundred women with a singleton pregnancy need to be randomized. Analysis will be done by intention to treat.Discussion: The APOSTEL VI trial will provide evidence whether a pessary is effective in preventing preterm birth in women who did not deliver 48 h after admission for threatened preterm labor and who remain at high risk for preterm birth.Trial Registration: Trial is registered at the Dutch Trial Register: http://www.trialregister.nl , NTR4210, date of registration: October 16th 2013. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. Early nasogastric tube feeding in optimising treatment for hyperemesis gravidarum: the MOTHER randomised controlled trial (Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding).
- Author
-
Grooten, Iris J., Mol, Ben W., van der Post, Joris A. M., Ris-Stalpers, Carrie, Kok, Marjolein, Bais, Joke M. J., Bax, Caroline J., Duvekot, Johannes J., Bremer, Henk A., Porath, Martina M., Heidema, Wieteke M., Bloemenkamp, Kitty W. M., Scheepers, Hubertina C. J., Franssen, Maureen T. M., Oudijk, Martijn A., Roseboom, Tessa J., and Painter, Rebecca C.
- Subjects
NASOENTERAL tubes ,TUBE feeding ,MORNING sickness treatment ,RANDOMIZED controlled trials ,HEALTH outcome assessment ,REFEEDING syndrome ,BIRTH weight ,COMPARATIVE studies ,ENTERAL feeding ,FLUID therapy ,GESTATIONAL age ,LENGTH of stay in hospitals ,INGESTION ,RESEARCH methodology ,EVALUATION of medical care ,MEDICAL cooperation ,MEDICAL protocols ,MORNING sickness ,NAUSEA ,PREGNANCY ,QUALITY of life ,RESEARCH ,STATISTICAL sampling ,GASTRIC intubation ,WEIGHT gain ,EVALUATION research ,TREATMENT effectiveness ,SEVERITY of illness index ,PATIENT readmissions - Abstract
Background: Hyperemesis gravidarum (HG), or intractable vomiting during pregnancy, is the single most frequent cause of hospital admission in early pregnancy. HG has a major impact on maternal quality of life and has repeatedly been associated with poor pregnancy outcome such as low birth weight. Currently, women with HG are admitted to hospital for intravenous fluid replacement, without receiving specific nutritional attention. Nasogastric tube feeding is sometimes used as last resort treatment. At present no randomised trials on dietary or rehydration interventions have been performed. Small observational studies indicate that enteral tube feeding may have the ability to effectively treat dehydration and malnutrition and alleviate nausea and vomiting symptoms. We aim to evaluate the effectiveness of early enteral tube feeding in addition to standard care on nausea and vomiting symptoms and pregnancy outcomes in HG patients.Methods/design: The MOTHER trial is a multicentre open label randomised controlled trial ( www.studies-obsgyn.nl/mother ). Women ≥ 18 years hospitalised for HG between 5 + 0 and 19 + 6 weeks gestation are eligible for participation. After informed consent participants are randomly allocated to standard care with intravenous rehydration or early enteral tube feeding in addition to standard care. All women keep a weekly diary to record symptoms and dietary intake until 20 weeks gestation. The primary outcome will be neonatal birth weight. Secondary outcomes will be the 24-h Pregnancy Unique Quantification of Emesis and nausea score (PUQE-24), maternal weight gain, dietary intake, duration of hospital stay, number of readmissions, quality of life and side-effects. Also gestational age at birth, placental weight, umbilical cord plasma lipid concentration and neonatal morbidity will be evaluated. Analysis will be according to the intention to treat principle.Discussion: With this trial we aim to clarify whether early enteral tube feeding is more effective in treating HG than intravenous rehydration alone and improves pregnancy outcome.Trial Registration: Trial Registration Number: NTR4197 . Date of registration: October 2(nd) 2013. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
8. Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL - III trial).
- Author
-
van Teeffelen, Augustinus S. P., van der Ham, David P., Willekes, Christine, Nasiry, Salwan Al, Nijhuis, Jan G., van Kuijk, Sander, Schuyt, Ewoud, Mulder, Twan L. M., Franssen, Maureen T. M., Oepkes, Dick, Jansen, Fenna A. R., Woiski, Mallory D., Bekker, Mireille N., Bax, Caroline J., Porath, Martina M., de Laat, Monique W. M., Mol, Ben W., and Pajkrt, Eva
- Abstract
Background: Babies born after midtrimester preterm prelabour rupture of membranes (PPROM) are at risk to develop neonatal pulmonary hypoplasia. Perinatal mortality and morbidity after this complication is high. Oligohydramnios in the midtrimester following PPROM is considered to cause a delay in lung development. Repeated transabdominal amnioinfusion with the objective to alleviate oligohydramnios might prevent this complication and might improve neonatal outcome. Methods/Design: Women with PPROM and persisting oligohydramnios between 16 and 24 weeks gestational age will be asked to participate in a multi-centre randomised controlled trial. Intervention: random allocation to (repeated) abdominal amnioinfusion (intervention) or expectant management (control). The primary outcome is perinatal mortality. Secondary outcomes are lethal pulmonary hypoplasia, non-lethal pulmonary hypoplasia, survival till discharge from NICU, neonatal mortality, chronic lung disease (CLD), number of days ventilatory support, necrotizing enterocolitis (NEC), periventricular leucomalacia (PVL) more than grade I, severe intraventricular hemorrhage (IVH) more than grade II, proven neonatal sepsis, gestational age at delivery, time to delivery, indication for delivery, successful amnioinfusion, placental abruption, cord prolapse, chorioamnionitis, fetal trauma due to puncture. The study will be evaluated according to intention to treat. To show a decrease in perinatal mortality from 70% to 35%, we need to randomise two groups of 28 women (two sided test, â-error 0.2 and á-error 0.05). Discussion: This study will answer the question if (repeated) abdominal amnioinfusion after midtrimester PPROM with associated oligohydramnios improves perinatal survival and prevents pulmonary hypoplasia and other neonatal morbidities. Moreover, it will assess the risks associated with this procedure. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial).
- Author
-
van Vliet, Elvira O. G., Schuit, Ewoud, Heida, Karst Y., Opmeer, Brent C., Kok, Marjolein, Gyselaers, Wilfried, Porath, Martina M., Woiski, Mallory, Bax, Caroline J., Bloemenkamp, Kitty W. M., Scheepers, Hubertina C. J., Jaquemyn, Yves, van Beek, Erik, Duvekot, Hans J. J., Franssen, Maureen T. M., Bijvank, Bas N., Kok, Joke H., Franx, Arie, Mol, Ben Willem J., and Oudijk, Martijn A.
- Abstract
Background: Preterm birth is the most common cause of neonatal morbidity and mortality. Postponing delivery for 48 hours with tocolytics to allow for maternal steroid administration and antenatal transportation to a centre with neonatal intensive care unit facilities is the standard treatment for women with threatening preterm delivery in most centres. However, there is controversy as to which tocolytic agent is the drug of first choice. Previous trials have focused on tocolytic efficacy and side effects, and are probably underpowered to detect clinically meaningfull differences in neonatal outcome. Thus, the current evidence is inconclusive to support a balanced recommendation for clinical practice. This multicenter randomised clinical trial aims to compare nifedipine and atosiban in terms of neonatal outcome, duration of pregnancy and maternal side effects. Methods/Design: The Apostel III trial is a nationwide multicenter randomised controlled study. Women with threatened preterm labour (gestational age 25 - 34 weeks) defined as at least 3 contractions per 30 minutes, and 1) a cervical length of = 10 mm or 2) a cervical length of 11-30 mm and a positive Fibronectin test or 3) ruptured membranes will be randomly allocated to treatment with nifedipine or atosiban. Primary outcome is a composite measure of severe neonatal morbidity and mortality. Secondary outcomes will be time to delivery, gestational age at delivery, days on ventilation support, neonatal intensive care (NICU) admittance, length admission in neonatal intensive care, total days in hospital until 3 months corrected age, convulsions, apnoea, asphyxia, proven meningitis, pneumothorax, maternal side effects and costs. Furthermore, an economic evaluation of the treatment will be performed. Analysis will be by intention to treat principle. The power calculation is based on an expected 10% difference in the prevalence of adverse neonatal outcome. This implies that 500 women have to be randomised (two sided test, ß 0.2 at alpha 0.05). Discussion: This trial will provide evidence on the optimal drug of choice in acute tocolysis in threatening preterm labour. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. Serovar D and E of serogroup B induce highest serological responses in urogenital Chlamydia trachomatis infections.
- Author
-
Verweij, Stephan P., Lanjouw, Esmée, Bax, Caroline J., Quint, Koen D., Oostvogel, Paul M., Joep Dörr, P., Pleijster, Jolein, de Vries, Henry J. C., Peters, Remco P. H., Ouburg, Sander, and Morré, Servaas A.
- Subjects
CHLAMYDIA trachomatis ,SEXUALLY transmitted disease diagnosis ,ENZYME-linked immunosorbent assay ,OPACITY (Optics) ,SEROLOGY - Abstract
Background Chlamydia trachomatis is the most prevalent bacterial sexually transmitted infection (STI) worldwide. A strong link between C. trachomatis serogroup/serovar and serological response has been suggested in a previous preliminary study. The aim of the current study was to confirm and strengthen those findings about serological IgG responses in relation to C. trachomatis serogroups and serovars. Methods The study population (n = 718) consisted of two patient groups with similar characteristics of Dutch STI clinic visitors. We performed genotyping of serovars and used titre based and quantitative commercially available ELISA kits (medac Diagnostika) to determine specific serum IgG levels. Optical density (OD) values generated by both tests were used to calculate the IgG titres (cut-off 1:50). Analyses were conducted stratified by gender. Results We observed very significant differences when comparing the median IgG titres of three serogroups, B, C and I: in women for B vs. C: p < 0.0001 (median titres B 200 vs. C <50); B vs. I: p < 0.0001 (200 vs. 50), and in men for B vs. C: p = 0.0006 (150 vs. <50); B vs. I: p = 0.0001 (150 vs. <50); C vs. I was not significant for both sexes. Serovars D and E of serogroup B had the highest median IgG titres compared to the other serovars in both men and women: 200 and 200 vs. ≤ 100 for women and 100 and 200 vs. ≤ 75 for men, respectively. Conclusions This study shows that B group serovars induce higher serological responses compared to the C and I group serovars in vivo in both men and women. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Remifentanil patient controlled analgesia versus epidural analgesia in labour. A multicentre randomized controlled trial.
- Author
-
Freeman LM, Bloemenkamp KW, Franssen MT, Papatsonis DN, Hajenius PJ, van Huizen ME, Bremer HA, van den Akker ES, Woiski MD, Porath MM, van Beek E, Schuitemaker N, van der Salm PC, Fong BF, Radder C, Bax CJ, Sikkema M, van den Akker-van Marle ME, van Lith JM, Lopriore E, Uildriks RJ, Struys MM, Mol BW, Dahan A, and Middeldorp JM
- Subjects
- Adolescent, Adult, Analgesia, Obstetrical adverse effects, Analgesics, Opioid adverse effects, Analgesics, Opioid economics, Cost-Benefit Analysis, Female, Humans, Infant, Newborn, Labor, Obstetric, Pain Measurement, Patient Satisfaction economics, Piperidines adverse effects, Piperidines economics, Pregnancy, Remifentanil, Research Design, Young Adult, Analgesia, Epidural adverse effects, Analgesia, Epidural economics, Analgesia, Obstetrical methods, Analgesia, Patient-Controlled adverse effects, Analgesia, Patient-Controlled economics, Analgesics, Opioid therapeutic use, Pain drug therapy, Piperidines therapeutic use
- Abstract
Background: Pain relief during labour is a topic of major interest in the Netherlands. Epidural analgesia is considered to be the most effective method of pain relief and recommended as first choice. However its uptake by pregnant women is limited compared to other western countries, partly as a result of non-availability due to logistic problems. Remifentanil, a synthetic opioid, is very suitable for patient controlled analgesia. Recent studies show that epidural analgesia is superior to remifentanil patient controlled analgesia in terms of pain intensity score; however there was no difference in satisfaction with pain relief between both treatments., Methods/design: The proposed study is a multicentre randomized controlled study that assesses the cost-effectiveness of remifentanil patient controlled analgesia compared to epidural analgesia. We hypothesize that remifentanil patient controlled analgesia is as effective in improving pain appreciation scores as epidural analgesia, with lower costs and easier achievement of 24 hours availability of pain relief for women in labour and efficient pain relief for those with a contraindication for epidural analgesia.Eligible women will be informed about the study and randomized before active labour has started. Women will be randomly allocated to a strategy based on epidural analgesia or on remifentanil patient controlled analgesia when they request pain relief during labour. Primary outcome is the pain appreciation score, i.e. satisfaction with pain relief.Secondary outcome parameters are costs, patient satisfaction, pain scores (pain-intensity), mode of delivery and maternal and neonatal side effects.The economic analysis will be performed from a short-term healthcare perspective. For both strategies the cost of perinatal care for mother and child, starting at the onset of labour and ending ten days after delivery, will be registered and compared., Discussion: This study, considering cost effectiveness of remifentanil as first choice analgesia versus epidural analgesia, could strongly improve the care for 180.000 women, giving birth in the Netherlands yearly by giving them access to pain relief during labour, 24 hours a day., Trial Registration Number: Dutch Trial Register NTR2551, http://www.trialregister.nl.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.